Literature DB >> 32146823

The Epidemiological and Clinical Characteristics of Hand, Foot, and Mouth Disease in Hangzhou, China, 2016 to 2018.

Jie Wang1, Jun Zhou1, Guoliang Xie2,3, Shufa Zheng2,3, Bin Lou2,3, Yu Chen2,3, Yidong Wu1.   

Abstract

Hand, foot, and mouth disease (HFMD) is most frequently caused by several serotypes of human enterovirus (EV) including Enterovirus 71 (EV-A71), coxsackievirus A16 (CV-A16), or other types of EV. The aim of this study was to determine the epidemiological characteristics of HFMD and to describe the epidemiologic characteristics of HFMD among severe and mild cases. We collected 4760 HFMD cases in Hangzhou from 2016 to 2018. Specimens from these cases were collected and tested for EV-A71, CV-A16, CV-A6, CV-A10, CV-A2, and CV-A5 by reverse transcriptase polymerase chain reaction. From 2016 to 2018, the prevalence of HFMD was seasonal each year. Among the 4760 probable HFMD cases, 3559 cases were confirmed (74.8%), including 426 cases of EV-A71 infections (8.9%), 249 cases of CV-A16 infections (5.2%), and 2884 cases of other EV infections (60.6%). The percentage of other EV infections was more than 80%, which increased year by year. Random selection of samples for detection of other EV infections in 2017 and 2018, among the 1297 cases, showed there were 835 (64.4%) cases of CV-A6 infections, 177 (13.6%) cases of CV-A10 infections, 100 (7.7%) cases of CV-A2 infections, 40 (3.1%) cases of CV-A5 infections, 3 (0.02 %) cases of mixed infections, and 11.0% untyped EV infections. Preschool children were still the primary population susceptible to HFMD. In severe cases, EV-A71 infection was the main cause. Characterizing the epidemiology and the relationship between severe and common cases of HFMD would provide relevant evidences for the prevention and treatment of HFMD.

Entities:  

Keywords:  coxsackievirus A16; enterovirus 71; foot and mouth disease; hand; other enterovirus infections

Mesh:

Year:  2020        PMID: 32146823     DOI: 10.1177/0009922820910822

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  5 in total

1.  Epidemiological characteristics, routine laboratory diagnosis, clinical signs and risk factors for hand, -foot -and -mouth disease: A systematic review and meta-analysis.

Authors:  Zhijie Yi; Shujun Pei; Wenshuai Suo; Xiaoyang Wang; Zengyuan Huang; Aihua Yi; Bohao Wang; Zhiquan He; Ruolin Wang; Yi Li; Wei Fan; Xueyong Huang
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.240

2.  Clinical characteristics of 68 children with atypical hand, foot, and mouth disease caused by coxsackievirus A6: a single-center retrospective analysis.

Authors:  Fang-Fang Cheng; Bing-Bing Zhang; Meng-Lu Cao; Qian Zhang; Qing-Hui Chen; Zhao-Fang Hui; Jian-Mei Tian; Wen-Hua Yan
Journal:  Transl Pediatr       Date:  2022-09

3.  Epidemiological and etiological characteristics of mild hand, foot and mouth disease in children under 7 years old, Nanjing, China, 2010-2019.

Authors:  Junjun Wang; Songning Ding; Weijia Xie; Taiwu Wang; Ying Qin; Jiandong Zheng; Xiaokun Yang; Hongting Zhao; Zhibin Peng; Tao Ma
Journal:  Arch Public Health       Date:  2022-10-08

4.  Optimizing laboratory-based surveillance networks for monitoring multi-genotype or multi-serotype infections.

Authors:  Qu Cheng; Philip A Collender; Alexandra K Heaney; Aidan McLoughlin; Yang Yang; Yuzi Zhang; Jennifer R Head; Rohini Dasan; Song Liang; Qiang Lv; Yaqiong Liu; Changhong Yang; Howard H Chang; Lance A Waller; Jon Zelner; Joseph A Lewnard; Justin V Remais
Journal:  PLoS Comput Biol       Date:  2022-09-27       Impact factor: 4.779

5.  First evidence of enterovirus A71 and echovirus 30 in Uruguay and genetic relationship with strains circulating in the South American region.

Authors:  Andrés Lizasoain; Daiana Mir; Matías Salvo; Viviana Bortagaray; Gisela Masachessi; Adrián Farías; Nélida Rodríguez-Osorio; Silvia Nates; Matías Victoria; Rodney Colina
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.